All Lynelle Hoch articles
-
NewsBristol Myers Squibb wins fifth US approval for CAR T cell therapy Breyanzi
The FDA’s latest authorisation makes it the most widely approved of any CD19-directed CAR T therapy in cancer.
-
News
Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn
Gains access to OTX-201, a preclinical CAR T therapy being developed to treat autoimmune diseases.
-
NewsBMS inks CAR T cell therapy manufacturing deal with Cellares
Bristol Myers Squibb has signed a worldwide capacity reservation and supply agreement with Cellares for CAR T-cell therapy manufacturing.
-
NewsFDA approves new cell therapy manufacturing plant
Bristol Myers Squibb has received approval from the US FDA to begin commercial production at its newest cell therapy manufacturing site.
-
NewsBristol Myers Squibb boosts CAR T therapy manufacturing capabilities
Securing in-house viral vector production capabilities in the US is set to help Bristol Myers Squibb manufacture its two CAR T-cell therapies.